Global Human Rabies Vaccine Market Overview
As per MRFR analysis, the Human Rabies Vaccine Market Size was estimated at 0.51 (USD Billion) in 2022. The Human Rabies Vaccine Market Industry is expected to grow from 0.55 (USD Billion) in 2023 to 1.01 (USD Billion) by 2032. The Human Rabies Vaccine Market CAGR (growth rate) is expected to be around 6.98% during the forecast period (2024 - 2032).
Key Human Rabies Vaccine Market Trends Highlighted
Globally, the human rabies vaccine market exhibits promising growth prospects. Key market drivers include increasing awareness about rabies prevention and vaccination, expanding immunization programs in developing regions, and the rise in animal-borne diseases.
Governments and non-profit organizations are actively involved in promoting rabies awareness campaigns, which has contributed to the increased demand for vaccines. Additionally, technological advancements, such as the development of new vaccine formulations and delivery methods, are creating opportunities for market growth.
In recent times, trends in the human rabies vaccine market include the emergence of needle-free vaccination systems, advancements in vaccine storage and transportation, and the rising focus on personalized vaccination approaches tailored to specific population groups.
The market is expected to witness continued growth in the coming years due to these factors, providing opportunities for manufacturers and suppliers to expand their offerings and cater to the evolving needs of the market.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
Human Rabies Vaccine Market Drivers
Increasing Incidence of Rabies
Rabies is a fatal viral disease that affects the central nervous system. It is transmitted through the bite of an infected animal, most commonly dogs. The World Health Organization (WHO) estimates that rabies causes approximately 59,000 deaths each year, primarily in Asia and Africa.
The increasing incidence of rabies is a major driver of the Human Rabies Vaccine Market. The rising number of rabies cases is due to several factors, including the growing population of stray dogs, the lack of access to rabies vaccination in some regions, and the increasing movement of people and animals across borders. As the incidence of rabies continues to rise, the demand for human rabies vaccines is expected to grow.
Growing Awareness of Rabies Prevention
The growing awareness of rabies prevention is another major driver of the Human Rabies Vaccine Market. Public health campaigns and educational programs have helped to raise awareness of the importance of rabies vaccination.
As more people become aware of the risks of rabies and the benefits of vaccination, the demand for human rabies vaccines is expected to increase. The Human Rabies Vaccine Market Industry includes key players such as Sanofi Pasteur, Merck & Co., Inc., and GSK.
Government Initiatives to Control Rabies
Government initiatives to control rabies are also driving the growth of the Human Rabies Vaccine Market. Many governments have implemented mandatory rabies vaccination programs for dogs and other animals.
These programs have helped to reduce the incidence of rabies in some regions. However, rabies remains a major problem in many developing countries, where access to rabies vaccination is limited. As governments continue to implement rabies control programs, the demand for human rabies vaccines is expected to increase in these regions.
Human Rabies Vaccine Market Segment Insights
Human Rabies Vaccine Market Vaccine Type Insights
The market is segmented based on vaccine type into killed virus vaccine, modified live virus vaccine, and recombinant vaccine. Killed Virus Vaccine: Killed virus vaccines are produced by inactivating the rabies virus using chemicals or heat.
They are the most commonly used type of rabies vaccine and are highly effective in preventing the disease. Killed virus vaccines are generally well-tolerated and have a low risk of side effects.
Modified Live Virus Vaccine: Modified live virus vaccines are produced by weakening the rabies virus in the laboratory. They are less commonly used than killed virus vaccines but are generally more effective in preventing rabies. Modified live virus vaccines can cause more side effects than killed virus vaccines, but these side effects are usually mild.
Recombinant Vaccine: Recombinant vaccines are produced using genetic engineering techniques. They are the newest type of rabies vaccine and are highly effective in preventing the disease. Recombinant vaccines are generally well-tolerated and have a low risk of side effects.
The killed virus vaccine segment held the largest share of the Human Rabies Vaccine Market in 2023 due to its widespread use and high efficacy.
However, the modified live virus vaccine segment is expected to grow at a faster CAGR during the forecast period due to its increased effectiveness and lower risk of side effects. The recombinant vaccine segment is also expected to grow at a significant CAGR during the forecast period due to its high efficacy and low risk of side effects.
Overall, the Human Rabies Vaccine Market is expected to grow at a steady pace during the forecast period, driven by the increasing demand for rabies vaccines in developing countries and the development of new and more effective vaccines.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
Human Rabies Vaccine Market Route of Administration Insights
Intramuscular Injection accounted for the largest revenue share in 2023. Intramuscular Injection is the most common route of administration for rabies vaccines. It is a safe and effective way to deliver the vaccine to the body. The vaccine is injected into the muscle, where it is absorbed into the bloodstream.
Intradermal Injection is another common route of administration for rabies vaccines. It is less painful than intramuscular injection, but it is not as effective. The vaccine is injected into the skin, where it is absorbed into the bloodstream.
Subcutaneous Injection is the least common route of administration for rabies vaccines. It is less painful than intramuscular injection, but it is not as effective. The vaccine is injected under the skin, where it is absorbed into the bloodstream.
Human Rabies Vaccine Market Immunoglobulins Insights
Immunoglobulins, comprising Human Rabies Immunoglobulin (HRIG) and Equine Rabies Immunoglobulin (ERIG), play a crucial role in the Human Rabies Vaccine Market. HRIG, derived from human plasma, offers high potency and a low risk of allergic reactions. ERIG, obtained from horse serum, is a more cost-effective option.
In 2023, the Immunoglobulins segment held a significant market share, valued at approximately USD 0.29 billion. It is projected to grow at a CAGR of 6.98%, reaching an estimated USD 0.51 billion by 2032. The rising incidence of rabies, particularly in developing countries, coupled with increased awareness and vaccination programs, is driving market growth.
Additionally, the development of new and improved immunoglobulin formulations is expected to further boost segment expansion
Human Rabies Vaccine Market Application Insights
The Human Rabies Vaccine Market size for Pre-Exposure Prophylaxis is expected to grow from an estimated USD 0.36 billion in 2023 to USD 0.58 billion by 2032, at a CAGR of 6.1%. The Human Rabies Vaccine Market size for Post-Exposure Prophylaxis is expected to grow from USD 0.19 billion in 2023 to USD 0.43 billion by 2032, at a CAGR of 7.6%.
The market growth is attributed to the increasing incidence of rabies, the rising awareness of rabies prevention, and the availability of effective vaccines. The Pre-Exposure Prophylaxis segment is expected to hold a larger market share due to the increasing adoption of pre-exposure vaccination among travelers, healthcare workers, and individuals living in endemic areas.
The Post-Exposure Prophylaxis segment is expected to experience significant growth due to the rising incidence of animal bites and the need for immediate post-exposure treatment.
Human Rabies Vaccine Market Dosage Form Insights
The Human Rabies Vaccine Market is segmented by Dosage Form into Vials and Pre-Filled Syringes. Among these, the Vials segment held a larger market share in 2023, owing to the widespread availability and ease of administration of vials in various healthcare settings. However, the Pre-Filled Syringes segment is anticipated to exhibit a higher growth rate during the forecast period.
The growing adoption of pre-filled syringes for subcutaneous administration and the increasing convenience they offer in terms of accurate dosing and ease of handling are driving the growth of this segment.
In 2023, the Human Rabies Vaccine Market for Vials was valued at 0.31 USD Billion, and it is projected to reach 0.49 USD Billion by 2032, exhibiting a CAGR of 6.04%. The Pre-Filled Syringes segment, valued at 0.24 USD Billion in 2023, is estimated to reach 0.52 USD Billion by 2032, growing at a CAGR of 8.37%.
Human Rabies Vaccine Market Regional Insights
North America dominated the market share in 2023, owing to the presence of a well-established healthcare infrastructure, a high incidence of rabies cases, and favorable government initiatives for rabies prevention and control.
Europe is projected to experience steady growth due to increasing awareness about rabies and government initiatives to eliminate the disease. APAC is expected to witness the fastest growth, driven by rising healthcare expenditure, growing population, and increasing urbanization.
South America and MEA are anticipated to contribute significantly to the market growth due to rising disposable income and improving healthcare access.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
Human Rabies Vaccine Market Key Players and Competitive Insights
Major players in the Human Rabies Vaccine Market industry are constantly involved in R&D activities to develop innovative and more effective vaccines. Leading Human Rabies Vaccine Market players are focused on expanding their product portfolio through strategic collaborations, partnerships, and acquisitions.
The Human Rabies Vaccine Market is highly competitive, with several key players accounting for a significant market share. These players are investing heavily in research and development to develop more advanced and effective vaccines. They are also expanding their geographic reach through strategic partnerships and collaborations.
Sanofi Pasteur, a leading company in the Human Rabies Vaccine Market, is committed to providing innovative and high-quality vaccines to prevent rabies. The company's rabies vaccine, RabAvert, is a highly effective vaccine that has been used to protect millions of people worldwide. Sanofi Pasteur is also actively involved in research and development to develop new and improved rabies vaccines.
Another key player in the Human Rabies Vaccine Market is Bavarian Nordic. The company's rabies vaccine, Rabipur, is a well-established and widely used vaccine that has been shown to be safe and effective. Bavarian Nordic is also developing a next-generation rabies vaccine that is expected to provide even better protection against the virus.
Key Companies in the Human Rabies Vaccine Market Include
- Biofabri
- Serum Institute of India Ltd
- Sanofi Pasteur
- Incepta Vaccine
- Hunan Changde BioPharmaceutical
- Bharat Biotech International Ltd
- GSK
- Bavarian Nordic
- Pfizer
- Pasteur Institute of Korea
- Sinovac Biotech
- Chengda Biopharm
- Bio Farma
- Abbott Laboratories
- J/Merck Sharp Dohme
Human Rabies Vaccine Market Industry Developments
Key factors driving growth include increasing awareness of rabies prevention, expanding vaccination programs, and technological advancements in vaccine development. Recent developments include the introduction of more effective and affordable rabies vaccines, such as the vero cell rabies vaccine.
Furthermore, strategic collaborations and partnerships between pharmaceutical companies and research institutions are fostering innovation and expanding market reach. Governments worldwide are prioritizing rabies control measures, leading to increased demand for human rabies vaccines.
Human Rabies Vaccine Market Segmentation Insights
- Human Rabies Vaccine Market Vaccine Type Outlook
- Killed Virus Vaccine
- Modified Live Virus Vaccine
- Recombinant Vaccine
- Human Rabies Vaccine Market Route of Administration Outlook
- Intramuscular Injection
- Intradermal Injection
- Subcutaneous Injection
- Human Rabies Vaccine Market Immunoglobulins Outlook
- Human Rabies Immunoglobulin (HRIG)
- Equine Rabies Immunoglobulin (ERIG)
- Human Rabies Vaccine Market Application Outlook
- Pre-Exposure Prophylaxis
- Post-Exposure Prophylaxis
- Human Rabies Vaccine Market Dosage Form Outlook
- Vials
- Pre-Filled Syringes
| Report Attribute/Metric |
Details |
| Market Size 2022 |
0.51(USD Billion) |
| Market Size 2023 |
0.55(USD Billion) |
| Market Size 2032 |
1.01(USD Billion) |
| Compound Annual Growth Rate (CAGR) |
6.98% (2024 - 2032) |
| Report Coverage |
Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| Base Year |
2023 |
| Market Forecast Period |
2024 - 2032 |
| Historical Data |
2019 - 2023 |
| Market Forecast Units |
USD Billion |
| Key Companies Profiled |
Biofabri, Serum Institute of India Ltd, Sanofi Pasteur, Incepta Vaccine, Hunan Changde BioPharmaceutical, Bharat Biotech International Ltd, GSK, Bavarian Nordic, Pfizer, Pasteur Institute of Korea, Sinovac Biotech, Chengda Biopharm, Bio Farma, Abbott Laboratories, J/Merck Sharp Dohme |
| Segments Covered |
Vaccine Type, Route of Administration, Immunoglobulins, Application, Dosage Form, Regional |
| Key Market Opportunities |
Increasing demand in endemic regions Rising incidence of rabies Expanding travel and tourism Government initiatives for rabies control Technological advancements in vaccine development |
| Key Market Dynamics |
Rising demand for preexposure prophylaxis Increasing incidence of rabies cases in developing countries Growth in the travel and tourism industry Focus on improving healthcare infrastructure Technological advancements |
| Countries Covered |
North America, Europe, APAC, South America, MEA |
Frequently Asked Questions (FAQ) :
The Human Rabies Vaccine Market size is expected to reach USD 1.01 billion by 2032, exhibiting a CAGR of 6.98% during the forecast period.
Asia Pacific is expected to dominate the Human Rabies Vaccine Market throughout the forecast period.
Increasing awareness about rabies, rising incidence of animal-borne diseases, and government initiatives to control rabies are primarily driving the growth of the market.
Human rabies vaccine is primarily used for pre-exposure and post-exposure prophylaxis against rabies virus infection.
Major players in the Human Rabies Vaccine Market include Sanofi Pasteur, Merck Co., Inc., GSK plc, and Biological E. Limited.
The Human Rabies Vaccine Market is anticipated to grow at a CAGR of 6.98% from 2024 to 2032.
The high cost of vaccination and lack of awareness in underdeveloped regions are some of the factors restraining market growth.
Challenges include the need for multiple doses, adverse reactions, and the emergence of new rabies variants.
Rising demand for combination vaccines, technological advancements, and increasing investments in RD present growth opportunities.
Key trends include the development of needle-free vaccines, advancements in vaccine delivery systems, and increasing collaborations between stakeholders.
